Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EVO101
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Series B Financing
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Details : The capital raised will support Evommune’s three prioritised pipeline programs targeting highly prevalent inflammatory diseases, including EVO101, a novel small molecule inhibitor of the IRAK4.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : EVO101
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Series B Financing
Lead Product(s) : PYX-201
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Pyxis Oncology
Deal Size : $152.0 million
Deal Type : Series B Financing
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
Details : Pyxis will use the proceeds from the financing to advance its differentiated portfolio of ADCs, including PYX-201 and PYX-203, both in-licensed from Pfizer, and PYX-202, recently in-licensed from LegoChem Biosciences.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
March 30, 2021
Lead Product(s) : PYX-201
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Pyxis Oncology
Deal Size : $152.0 million
Deal Type : Series B Financing
Reset All
